Busy Days Ahead for Sarepta Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 11:23AM CDT
Shares of the clinical-state biotech Sarepta Therapeutics have certainly been on a wild ride over the past year. And the underlying cause of this volatility has undoubtedly been the regulatory and clinical uncertainty regarding the company's...
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Sarepta's Loss Widens 59% as it Prepares Eteplirsen For a New Drug Application Filing
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 10:46AM CDT
Duchenne muscular dystrophy-focused biopharmaceutical company Sarepta Therapeutics reported its first-quarter results before the opening, telling the tale of a widening loss but a number of new regulatory moves on the horizon. For the quarter,...
Sarepta Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments
Business Wire - Thu May 08, 6:01AM CDT
--Multiple eteplirsen clinical studies in broader population of DMD patients to begin dosing later this year;
Sarepta Therapeutics to Present Company Overview at the 2014 Bank of America Merrill Lynch Healthcare Conference
Business Wire - Tue May 06, 7:30AM CDT
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV on Tuesday, May 13, 2014 at 10:40 a.m. Pacific Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Sarepta Therapeutics to Present Company Overview at the 2014 39th Annual Deutsche Bank Healthcare Conference
Business Wire - Tue Apr 29, 7:35AM CDT
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 39th Annual Deutsche Bank Healthcare Conference in Boston, MA on Wednesday, May 7, 2014 at 8:40 a.m. Eastern Time. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter for a fireside chat format.
Sarepta Therapeutics to Announce First Quarter 2014 Financial Results and Corporate Update on May 8, 2014
Business Wire - Tue Apr 29, 7:30AM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, May 8, 2014. Subsequently, at 8:00 a.m., Eastern Time, Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss first quarter financial results and to provide a corporate update.
Chris Garabedian Joins Board of Advisors of Nonprofit Organization Dedicated to Biotech History
GlobeNewswire - Mon Apr 28, 10:05AM CDT
The Life Sciences Foundation, a nonprofit organization dedicated to capturing the history, preserving the heritage and sharing the stories of biotechnology, appoints Chris Garabedian to its board of advisors.
Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014
Business Wire - Mon Apr 28, 7:31AM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, May 13, 2014, beginning at 11:00 a.m. EDT (8:00 a.m. PDT / 5:00 p.m. CEST).
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
This Week in Biotech: Is This the Return of Big M&A?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 2:15PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 26, 6:30AM CDT
Ho-hum? That might be the reaction of most to the overall market these days. You can bet that shareholders of these three health-care stocks aren't yawning, though. Each of them soared at least 27% this week. One stock leaped on a stunning reversal...
Sarepta's Still a Gamble, Even With FDA Reversal
Amy Ho, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
After a rollercoaster few months for Sarepta Therapeutic 's duchenne muscular dystrophy drug eteplirsen, the company appears to be back from the dead with the FDA detailing paths to a new drug application by the end of the year. Unsurprisingly,...
Sarepta Therapeutics prices public offering at USD38.00 per share
M2 - Thu Apr 24, 4:19AM CDT
Therapeutic company Sarepta Therapeutics (NasdaqGS:SRPT) said on Wednesday that it has priced a public offering of 2,650,000 shares of its common stock at USD38.00 per share.
Sarepta Therapeutics Announces Pricing of $100.7 Million Public Offering of Common Stock
Business Wire - Wed Apr 23, 8:17PM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-based therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 2,650,000 shares of its common stock at a price to the public of $38.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 397,500 shares of common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the aggregate net proceeds from the offering will be approximately $94.5 million, after deducting the underwriting discount and estimated offering expenses payable by Sarepta, but excluding any exercise of the underwriters' option. The offering is expected to close on or about April 29, 2014, subject to customary closing conditions.
Technical Data on Top Gainers -- Research on Rent-A-Center, Sarepta Therapeutics, Chelsea Therapeutics Intl., and SunPower
PR Newswire - Wed Apr 23, 10:32AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Rent-A-Center Inc. (NASDAQ: RCII), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Chelsea Therapeutics International Ltd (NASDAQ: CHTP) and SunPower Corp. (NASDAQ: SPWR). Free technical research on RCII, SRPT, CHTP and SPWR can be downloaded upon signing up at:
Sarepta Therapeutics intends to offer USD100m common shares in public offering
M2 - Wed Apr 23, 3:01AM CDT
RNA therapeutics company Sarepta Therapeutics (NasdaqGS:SRPT) said on Tuesday that it plans to issue up to USD100m of its common stock in an underwritten public offering.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 22, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: